PhRMA Moves To Vanquish FTC Rule Targeting Drugmakers

Law360, New York (February 10, 2014, 5:29 PM EST) -- The Pharmaceutical Research and Manufacturers of America on Friday urged a D.C. federal judge to vacate a Federal Trade Commission rule requiring pharmaceutical companies to report more exclusive patent licenses for antitrust approval under federal merger law, arguing that the agency lacks the authority to target specific sectors.

In a motion for summary judgment, the leading pharmaceutical trade group told the court that the November rule, which upped the reporting burden on its member companies, far exceeds the FTC's authority under the Hart-Scott-Rodino Act. That statute, according...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA v. FEDERAL TRADE COMMISSION


Case Number

1:13-cv-01974

Court

District Of Columbia

Nature of Suit

Administrative Procedure Act/Review or Appeal of Agency Decision

Judge

Beryl A. Howell

Date Filed

December 11, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.